ID   PCNA_HUMAN              Reviewed;         261 AA.
AC   P12004; B2R897; D3DW02;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 1.
DT   22-JUL-2015, entry version 181.
DE   RecName: Full=Proliferating cell nuclear antigen;
DE            Short=PCNA;
DE   AltName: Full=Cyclin;
GN   Name=PCNA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2882507; DOI=10.1073/pnas.84.6.1575;
RA   Almendral J.M., Huebsch D., Blundell P.A., Macdonald-Bravo H.,
RA   Bravo R.;
RT   "Cloning and sequence of the human nuclear protein cyclin: homology
RT   with DNA-binding proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:1575-1579(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2565339;
RA   Travali S., Ku D.H., Rizzo M.G., Ottavio L., Baserga R.,
RA   Calabretta B.;
RT   "Structure of the human gene for the proliferating cell nuclear
RT   antigen.";
RL   J. Biol. Chem. 264:7466-7472(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone marrow, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 1-26.
RX   PubMed=2882422; DOI=10.1038/326471a0;
RA   Prelich G., Kostura M., Marshak D.R., Mathews M.B., Stillman B.;
RT   "The cell-cycle regulated proliferating cell nuclear antigen is
RT   required for SV40 DNA replication in vitro.";
RL   Nature 326:471-475(1987).
RN   [9]
RP   PROTEIN SEQUENCE OF 169-181, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [10]
RP   INTERACTION WITH ERCC5/XPG.
RX   PubMed=9305916; DOI=10.1074/jbc.272.39.24522;
RA   Gary R., Ludwig D.L., Cornelius H.L., MacInnes M.A., Park M.S.;
RT   "The DNA repair endonuclease XPG binds to proliferating cell nuclear
RT   antigen (PCNA) and shares sequence elements with the PCNA-binding
RT   regions of FEN-1 and cyclin-dependent kinase inhibitor p21.";
RL   J. Biol. Chem. 272:24522-24529(1997).
RN   [11]
RP   INTERACTION WITH DNMT1.
RX   PubMed=9302295; DOI=10.1126/science.277.5334.1996;
RA   Chuang L.S.-H., Ian H.-I., Koh T.-W., Ng H.-H., Xu G., Li B.F.L.;
RT   "Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for
RT   p21WAF1.";
RL   Science 277:1996-2000(1997).
RN   [12]
RP   INTERACTION WITH CDC6.
RX   PubMed=9566895;
RA   Saha P., Chen J., Thome K.C., Lawlis S.J., Hou Z.H., Hendricks M.,
RA   Parvin J.D., Dutta A.;
RT   "Human CDC6/Cdc18 associates with Orc1 and cyclin-cdk and is
RT   selectively eliminated from the nucleus at the onset of S phase.";
RL   Mol. Cell. Biol. 18:2758-2767(1998).
RN   [13]
RP   INTERACTION WITH APEX2.
RX   PubMed=11376153; DOI=10.1093/nar/29.11.2349;
RA   Tsuchimoto D., Sakai Y., Sakumi K., Nishioka K., Sasaki M.,
RA   Fujiwara T., Nakabeppu Y.;
RT   "Human APE2 protein is mostly localized in the nuclei and to some
RT   extent in the mitochondria, while nuclear APE2 is partly associated
RT   with proliferating cell nuclear antigen.";
RL   Nucleic Acids Res. 29:2349-2360(2001).
RN   [14]
RP   INTERACTION WITH POLK.
RX   PubMed=11784855; DOI=10.1128/MCB.22.3.784-791.2002;
RA   Haracska L., Unk I., Johnson R.E., Phillips B.B., Hurwitz J.,
RA   Prakash L., Prakash S.;
RT   "Stimulation of DNA synthesis activity of human DNA polymerase kappa
RT   by PCNA.";
RL   Mol. Cell. Biol. 22:784-791(2002).
RN   [15]
RP   INTERACTION WITH DNTTIP2.
RX   PubMed=12786946; DOI=10.1046/j.1365-2443.2003.00656.x;
RA   Fujita K., Shimazaki N., Ohta Y., Kubota T., Ibe S., Toji S.,
RA   Tamai K., Fujisaki S., Hayano T., Koiwai O.;
RT   "Terminal deoxynucleotidyltransferase forms a ternary complex with a
RT   novel chromatin remodeling protein with 82 kDa and core histone.";
RL   Genes Cells 8:559-571(2003).
RN   [16]
RP   INTERACTION WITH POLDIP2.
RC   TISSUE=Placenta;
RX   PubMed=12522211; DOI=10.1074/jbc.M208694200;
RA   Liu L., Rodriguez-Belmonte E.M., Mazloum N., Xie B., Lee M.Y.W.T.;
RT   "Identification of a novel protein, PDIP38, that interacts with the
RT   p50 subunit of DNA polymerase delta and proliferating cell nuclear
RT   antigen.";
RL   J. Biol. Chem. 278:10041-10047(2003).
RN   [17]
RP   INTERACTION WITH EXO1.
RX   PubMed=15225546; DOI=10.1016/j.molcel.2004.06.016;
RA   Dzantiev L., Constantin N., Genschel J., Iyer R.R., Burgers P.M.,
RA   Modrich P.;
RT   "A defined human system that supports bidirectional mismatch-provoked
RT   excision.";
RL   Mol. Cell 15:31-41(2004).
RN   [18]
RP   UBIQUITINATION, AND INTERACTION WITH POLH.
RX   PubMed=15149598; DOI=10.1016/S1097-2765(04)00259-X;
RA   Kannouche P.L., Wing J., Lehmann A.R.;
RT   "Interaction of human DNA polymerase eta with monoubiquitinated PCNA:
RT   a possible mechanism for the polymerase switch in response to DNA
RT   damage.";
RL   Mol. Cell 14:491-500(2004).
RN   [19]
RP   INTERACTION WITH BAZ1B.
RX   PubMed=15543136; DOI=10.1038/ncb1196;
RA   Poot R.A., Bozhenok L., van den Berg D.L.C., Steffensen S.,
RA   Ferreira F., Grimaldi M., Gilbert N., Ferreira J., Varga-Weisz P.D.;
RT   "The Williams syndrome transcription factor interacts with PCNA to
RT   target chromatin remodelling by ISWI to replication foci.";
RL   Nat. Cell Biol. 6:1236-1244(2004).
RN   [20]
RP   INTERACTION WITH POLD1; POLD3 AND POLD4.
RX   PubMed=16510448; DOI=10.1074/jbc.M600322200;
RA   Li H., Xie B., Zhou Y., Rahmeh A., Trusa S., Zhang S., Gao Y.,
RA   Lee E.Y., Lee M.Y.;
RT   "Functional roles of p12, the fourth subunit of human DNA polymerase
RT   delta.";
RL   J. Biol. Chem. 281:14748-14755(2006).
RN   [21]
RP   INTERACTION WITH SHPRH, UBIQUITINATION AT LYS-164, AND MUTAGENESIS OF
RP   LYS-164.
RX   PubMed=17130289; DOI=10.1083/jcb.200606145;
RA   Motegi A., Sood R., Moinova H., Markowitz S.D., Liu P.P., Myung K.;
RT   "Human SHPRH suppresses genomic instability through proliferating cell
RT   nuclear antigen polyubiquitination.";
RL   J. Cell Biol. 175:703-708(2006).
RN   [22]
RP   INTERACTION WITH CDT1.
RX   PubMed=16949367; DOI=10.1016/j.molcel.2006.08.010;
RA   Jin J., Arias E.E., Chen J., Harper J.W., Walter J.C.;
RT   "A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2,
RT   which is required for S phase destruction of the replication factor
RT   Cdt1.";
RL   Mol. Cell 23:709-721(2006).
RN   [23]
RP   PHOSPHORYLATION AT TYR-211 BY EGFR, MUTAGENESIS OF TYR-211, AND
RP   INTERACTION WITH EGFR.
RX   PubMed=17115032; DOI=10.1038/ncb1501;
RA   Wang S.C., Nakajima Y., Yu Y.L., Xia W., Chen C.T., Yang C.C.,
RA   McIntush E.W., Li L.Y., Hawke D.H., Kobayashi R., Hung M.C.;
RT   "Tyrosine phosphorylation controls PCNA function through protein
RT   stability.";
RL   Nat. Cell Biol. 8:1359-1368(2006).
RN   [24]
RP   UBIQUITINATION AT LYS-164, AND MUTAGENESIS OF LYS-164.
RX   PubMed=17108083; DOI=10.1073/pnas.0608595103;
RA   Unk I., Hajdu I., Fatyol K., Szakal B., Blastyak A., Bermudez V.,
RA   Hurwitz J., Prakash L., Prakash S., Haracska L.;
RT   "Human SHPRH is a ubiquitin ligase for Mms2-Ubc13-dependent
RT   polyubiquitylation of proliferating cell nuclear antigen.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18107-18112(2006).
RN   [25]
RP   UBIQUITINATION.
RX   PubMed=18948756;
RA   Zhang S., Chea J., Meng X., Zhou Y., Lee E.Y.C., Lee M.Y.W.T.;
RT   "PCNA is ubiquitinated by RNF8.";
RL   Cell Cycle 7:3399-3404(2008).
RN   [26]
RP   INTERACTION WITH CDKN1A.
RX   PubMed=18794347; DOI=10.1101/gad.1676108;
RA   Abbas T., Sivaprasad U., Terai K., Amador V., Pagano M., Dutta A.;
RT   "PCNA-dependent regulation of p21 ubiquitylation and degradation via
RT   the CRL4Cdt2 ubiquitin ligase complex.";
RL   Genes Dev. 22:2496-2506(2008).
RN   [27]
RP   INTERACTION WITH DDX11.
RX   PubMed=18499658; DOI=10.1074/jbc.M802696200;
RA   Farina A., Shin J.H., Kim D.H., Bermudez V.P., Kelman Z., Seo Y.S.,
RA   Hurwitz J.;
RT   "Studies with the human cohesin establishment factor, ChlR1.
RT   Association of ChlR1 with Ctf18-RFC and Fen1.";
RL   J. Biol. Chem. 283:20925-20936(2008).
RN   [28]
RP   INTERACTION WITH CDKN1A.
RX   PubMed=18703516; DOI=10.1074/jbc.M806045200;
RA   Nishitani H., Shiomi Y., Iida H., Michishita M., Takami T.,
RA   Tsurimoto T.;
RT   "CDK inhibitor p21 is degraded by a proliferating cell nuclear
RT   antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV
RT   irradiation.";
RL   J. Biol. Chem. 283:29045-29052(2008).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH APEX2.
RX   PubMed=19443450; DOI=10.1093/nar/gkp357;
RA   Burkovics P., Hajdu I., Szukacsov V., Unk I., Haracska L.;
RT   "Role of PCNA-dependent stimulation of 3'-phosphodiesterase and 3'-5'
RT   exonuclease activities of human Ape2 in repair of oxidative DNA
RT   damage.";
RL   Nucleic Acids Res. 37:4247-4255(2009).
RN   [30]
RP   UBIQUITINATION, AND INTERACTION WITH HLTF.
RX   PubMed=18316726; DOI=10.1073/pnas.0800563105;
RA   Unk I., Hajdu I., Fatyol K., Hurwitz J., Yoon J.-H., Prakash L.,
RA   Prakash S., Haracska L.;
RT   "Human HLTF functions as a ubiquitin ligase for proliferating cell
RT   nuclear antigen polyubiquitination.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3768-3773(2008).
RN   [31]
RP   UBIQUITINATION, FUNCTION, INTERACTION WITH HLTF AND SHPRH, AND
RP   MUTAGENESIS OF LYS-164.
RX   PubMed=18719106; DOI=10.1073/pnas.0805685105;
RA   Motegi A., Liaw H.-J., Lee K.-Y., Roest H.P., Maas A., Wu X.,
RA   Moinova H., Markowitz S.D., Ding H., Hoeijmakers J.H.J., Myung K.;
RT   "Polyubiquitination of proliferating cell nuclear antigen by HLTF and
RT   SHPRH prevents genomic instability from stalled replication forks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12411-12416(2008).
RN   [32]
RP   INTERACTION WITH NUDT15, AND ACETYLATION AT LYS-14.
RX   PubMed=19419956; DOI=10.1074/jbc.M109.015289;
RA   Yu Y., Cai J.-P., Tu B., Wu L., Zhao Y., Liu X., Li L., McNutt M.A.,
RA   Feng J., He Q., Yang Y., Wang H., Sekiguchi M., Zhu W.-G.;
RT   "Proliferating cell nuclear antigen is protected from degradation by
RT   forming a complex with MutT Homolog2.";
RL   J. Biol. Chem. 284:19310-19320(2009).
RN   [33]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-77; LYS-80 AND LYS-248, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [34]
RP   UBIQUITINATION, AND MUTAGENESIS OF LYS-164.
RX   PubMed=20129063; DOI=10.1016/j.molcel.2009.12.018;
RA   Terai K., Abbas T., Jazaeri A.A., Dutta A.;
RT   "CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote
RT   translesion DNA synthesis.";
RL   Mol. Cell 37:143-149(2010).
RN   [35]
RP   INTERACTION WITH SETMAR.
RX   PubMed=20457750; DOI=10.1093/nar/gkq339;
RA   De Haro L.P., Wray J., Williamson E.A., Durant S.T., Corwin L.,
RA   Gentry A.C., Osheroff N., Lee S.H., Hromas R., Nickoloff J.A.;
RT   "Metnase promotes restart and repair of stalled and collapsed
RT   replication forks.";
RL   Nucleic Acids Res. 38:5681-5691(2010).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   INTERACTION WITH SMARCAD1.
RX   PubMed=21549307; DOI=10.1016/j.molcel.2011.02.036;
RA   Rowbotham S.P., Barki L., Neves-Costa A., Santos F., Dean W.,
RA   Hawkes N., Choudhary P., Will W.R., Webster J., Oxley D., Green C.M.,
RA   Varga-Weisz P., Mermoud J.E.;
RT   "Maintenance of silent chromatin through replication requires SWI/SNF-
RT   like chromatin remodeler SMARCAD1.";
RL   Mol. Cell 42:285-296(2011).
RN   [38]
RP   INTERACTION WITH KIAA0101.
RX   PubMed=21628590; DOI=10.1073/pnas.1106136108;
RA   Emanuele M.J., Ciccia A., Elia A.E., Elledge S.J.;
RT   "Proliferating cell nuclear antigen (PCNA)-associated KIAA0101/PAF15
RT   protein is a cell cycle-regulated anaphase-promoting complex/cyclosome
RT   substrate.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:9845-9850(2011).
RN   [39]
RP   INTERACTION WITH PARPBP, AND SUMOYLATION.
RX   PubMed=22153967; DOI=10.1016/j.molcel.2011.11.010;
RA   Moldovan G.L., Dejsuphong D., Petalcorin M.I., Hofmann K., Takeda S.,
RA   Boulton S.J., D'Andrea A.D.;
RT   "Inhibition of homologous recombination by the PCNA-interacting
RT   protein PARI.";
RL   Mol. Cell 45:75-86(2012).
RN   [40]
RP   INTERACTION WITH SPRTN.
RX   PubMed=22681887; DOI=10.1016/j.molcel.2012.05.020;
RA   Centore R.C., Yazinski S.A., Tse A., Zou L.;
RT   "Spartan/C1orf124, a reader of PCNA ubiquitylation and a regulator of
RT   UV-induced DNA damage response.";
RL   Mol. Cell 46:625-635(2012).
RN   [41]
RP   INTERACTION WITH ZRANB3.
RX   PubMed=22759634; DOI=10.1101/gad.193516.112;
RA   Weston R., Peeters H., Ahel D.;
RT   "ZRANB3 is a structure-specific ATP-dependent endonuclease involved in
RT   replication stress response.";
RL   Genes Dev. 26:1558-1572(2012).
RN   [42]
RP   INTERACTION WITH ZRANB3.
RX   PubMed=22705370; DOI=10.1016/j.molcel.2012.05.025;
RA   Yuan J., Ghosal G., Chen J.;
RT   "The HARP-like domain-containing protein AH2/ZRANB3 binds to PCNA and
RT   participates in cellular response to replication stress.";
RL   Mol. Cell 47:410-421(2012).
RN   [43]
RP   INTERACTION WITH KIAA0101.
RX   PubMed=23000965; DOI=10.1038/ncb2579;
RA   Povlsen L.K., Beli P., Wagner S.A., Poulsen S.L., Sylvestersen K.B.,
RA   Poulsen J.W., Nielsen M.L., Bekker-Jensen S., Mailand N.,
RA   Choudhary C.;
RT   "Systems-wide analysis of ubiquitylation dynamics reveals a key role
RT   for PAF15 ubiquitylation in DNA-damage bypass.";
RL   Nat. Cell Biol. 14:1089-1098(2012).
RN   [44]
RP   INTERACTION WITH ZRANB3.
RX   PubMed=22704558; DOI=10.1016/j.molcel.2012.05.024;
RA   Ciccia A., Nimonkar A.V., Hu Y., Hajdu I., Achar Y.J., Izhar L.,
RA   Petit S.A., Adamson B., Yoon J.C., Kowalczykowski S.C.,
RA   Livingston D.M., Haracska L., Elledge S.J.;
RT   "Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain
RT   genomic integrity after replication stress.";
RL   Mol. Cell 47:396-409(2012).
RN   [45]
RP   INTERACTION WITH CDKN1C.
RX   PubMed=22634751; DOI=10.1038/ng.2275;
RA   Arboleda V.A., Lee H., Parnaik R., Fleming A., Banerjee A.,
RA   Ferraz-de-Souza B., Delot E.C., Rodriguez-Fernandez I.A.,
RA   Braslavsky D., Bergada I., Dell'Angelica E.C., Nelson S.F.,
RA   Martinez-Agosto J.A., Achermann J.C., Vilain E.;
RT   "Mutations in the PCNA-binding domain of CDKN1C cause IMAGe
RT   syndrome.";
RL   Nat. Genet. 44:788-792(2012).
RN   [46]
RP   INTERACTION WITH ANKRD17.
RX   PubMed=23711367; DOI=10.1016/j.febslet.2013.05.037;
RA   Menning M., Kufer T.A.;
RT   "A role for the Ankyrin repeat containing protein Ankrd17 in Nod1- and
RT   Nod2-mediated inflammatory responses.";
RL   FEBS Lett. 587:2137-2142(2013).
RN   [47]
RP   INTERACTION WITH RTEL1, AND SUBCELLULAR LOCATION.
RX   PubMed=24115439; DOI=10.1126/science.1241779;
RA   Vannier J.B., Sandhu S., Petalcorin M.I., Wu X., Nabi Z., Ding H.,
RA   Boulton S.J.;
RT   "RTEL1 is a replisome-associated helicase that promotes telomere and
RT   genome-wide replication.";
RL   Science 342:239-242(2013).
RN   [48]
RP   INVOLVEMENT IN ATLD2, INTERACTION WITH FEN1; LIG1 AND ERCC5, VARIANT
RP   ATLD2 ILE-228, AND CHARACTERIZATION OF VARIANT ATDL2 ILE-228.
RX   PubMed=24911150; DOI=10.1172/JCI74593;
RA   Baple E.L., Chambers H., Cross H.E., Fawcett H., Nakazawa Y.,
RA   Chioza B.A., Harlalka G.V., Mansour S., Sreekantan-Nair A.,
RA   Patton M.A., Muggenthaler M., Rich P., Wagner K., Coblentz R.,
RA   Stein C.K., Last J.I., Taylor A.M., Jackson A.P., Ogi T.,
RA   Lehmann A.R., Green C.M., Crosby A.H.;
RT   "Hypomorphic PCNA mutation underlies a human DNA repair disorder.";
RL   J. Clin. Invest. 124:3137-3146(2014).
RN   [49]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [50]
RP   INTERACTION WITH FAM111A.
RX   PubMed=24561620; DOI=10.1038/ncb2918;
RA   Alabert C., Bukowski-Wills J.C., Lee S.B., Kustatscher G.,
RA   Nakamura K., de Lima Alves F., Menard P., Mejlvang J., Rappsilber J.,
RA   Groth A.;
RT   "Nascent chromatin capture proteomics determines chromatin dynamics
RT   during DNA replication and identifies unknown fork components.";
RL   Nat. Cell Biol. 16:281-293(2014).
RN   [51]
RP   FUNCTION, SUBUNIT, INTERACTION WITH CREBBP; EP300 AND POLD1,
RP   ACETYLATION, UBIQUITINATION, ASSOCIATION WITH CHROMATIN, AND
RP   MUTAGENESIS OF LYS-13; LYS-14; LYS-20; LYS-77 AND LYS-80.
RX   PubMed=24939902; DOI=10.1093/nar/gku533;
RA   Cazzalini O., Sommatis S., Tillhon M., Dutto I., Bachi A., Rapp A.,
RA   Nardo T., Scovassi A.I., Necchi D., Cardoso M.C., Stivala L.A.,
RA   Prosperi E.;
RT   "CBP and p300 acetylate PCNA to link its degradation with nucleotide
RT   excision repair synthesis.";
RL   Nucleic Acids Res. 42:8433-8448(2014).
RN   [52]
RP   METHYLATION.
RX   PubMed=25732820; DOI=10.1016/j.celrep.2015.01.054;
RA   Perry J.J., Ballard G.D., Albert A.E., Dobrolecki L.E., Malkas L.H.,
RA   Hoelz D.J.;
RT   "Human C6orf211 encodes Armt1, a protein carboxyl methyltransferase
RT   that targets PCNA and is linked to the DNA damage response.";
RL   Cell Rep. 10:1288-1296(2015).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).
RX   PubMed=8861913; DOI=10.1016/S0092-8674(00)81347-1;
RA   Gulbis J.M., Kelman Z., Hurwitz J., O'Donnell M., Kuriyan J.;
RT   "Structure of the C-terminal region of p21(WAF1/CIP1) complexed with
RT   human PCNA.";
RL   Cell 87:297-306(1996).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) IN COMPLEX WITH FEN1.
RX   PubMed=15616578; DOI=10.1038/sj.emboj.7600519;
RA   Sakurai S., Kitano K., Yamaguchi H., Hamada K., Okada K., Fukuda K.,
RA   Uchida M., Ohtsuka E., Morioka H., Hakoshima T.;
RT   "Structural basis for recruitment of human flap endonuclease 1 to
RT   PCNA.";
RL   EMBO J. 24:683-693(2005).
CC   -!- FUNCTION: Auxiliary protein of DNA polymerase delta and is
CC       involved in the control of eukaryotic DNA replication by
CC       increasing the polymerase's processibility during elongation of
CC       the leading strand. Induces a robust stimulatory effect on the 3'-
CC       5' exonuclease and 3'-phosphodiesterase, but not apurinic-
CC       apyrimidinic (AP) endonuclease, APEX2 activities. Has to be loaded
CC       onto DNA in order to be able to stimulate APEX2. Plays a key role
CC       in DNA damage response (DDR) by being conveniently positioned at
CC       the replication fork to coordinate DNA replication with DNA repair
CC       and DNA damage tolerance pathways (PubMed:24939902). Acts as a
CC       loading platform to recruit DDR proteins that allow completion of
CC       DNA replication after DNA damage and promote postreplication
CC       repair: Monoubiquitinated PCNA leads to recruitment of translesion
CC       (TLS) polymerases, while 'Lys-63'-linked polyubiquitination of
CC       PCNA is involved in error-free pathway and employs recombination
CC       mechanisms to synthesize across the lesion.
CC       {ECO:0000269|PubMed:18719106, ECO:0000269|PubMed:19443450,
CC       ECO:0000269|PubMed:24939902}.
CC   -!- SUBUNIT: Homotrimer (PubMed:24939902). Interacts with p300/EP300;
CC       the interaction occurs on chromatin in UV-irradiated damaged cells
CC       (PubMed:24939902). Interacts with CREBBP (via transactivation
CC       domain and C-terminus); the interaction occurs on chromatin in UV-
CC       irradiated damaged cells (PubMed:24939902). Interacts with POLD1
CC       (PubMed:24939902). Forms a complex with activator 1 heteropentamer
CC       in the presence of ATP. Interacts with EXO1, POLH, POLK, DNMT1,
CC       ERCC5, FEN1, CDC6 and POLDIP2. Interacts with APEX2; this
CC       interaction is triggered by reactive oxygen species and increased
CC       by misincorporation of uracil in nuclear DNA. Forms a ternary
CC       complex with DNTTIP2 and core histone. Interacts with KCTD10 and
CC       PPP1R15A. Interacts with POLD3 and POLD4. Interacts with BAZ1B;
CC       the interaction is direct. Interacts with HLTF and SHPRH.
CC       Interacts with NUDT15. Interaction is disrupted in response to UV
CC       irradiation and acetylation. Interacts with CDKN1A/p21(CIP1) and
CC       CDT1; interacts via their PIP-box which also recruits the DCX(DTL)
CC       complex. Interacts with DDX11. Interacts with EGFR; positively
CC       regulates PCNA. Interacts with PARPBP. Interacts (when
CC       ubiquitinated) with SPRTN; leading to enhance RAD18-mediated PCNA
CC       ubiquitination. Interacts (when polyubiquitinated) with ZRANB3.
CC       Interacts with SMARCAD1. Interacts with CDKN1C. Interacts with
CC       KIAA0101/PAF15 (via PIP-box). Interacts with RTEL1 (via PIP-box);
CC       the interaction is direct and essential for the suppression of
CC       telomere fragility. Interacts with FAM111A (via PIP-box); the
CC       interaction is direct and required for PCNA loading on chromatin
CC       binding. Interacts with LIG1. Interacts with SETMAR. Interacts
CC       with ANKRD17. {ECO:0000250, ECO:0000269|PubMed:11376153,
CC       ECO:0000269|PubMed:11784855, ECO:0000269|PubMed:12522211,
CC       ECO:0000269|PubMed:12786946, ECO:0000269|PubMed:15149598,
CC       ECO:0000269|PubMed:15225546, ECO:0000269|PubMed:15543136,
CC       ECO:0000269|PubMed:15616578, ECO:0000269|PubMed:16510448,
CC       ECO:0000269|PubMed:16949367, ECO:0000269|PubMed:17115032,
CC       ECO:0000269|PubMed:17130289, ECO:0000269|PubMed:18316726,
CC       ECO:0000269|PubMed:18499658, ECO:0000269|PubMed:18703516,
CC       ECO:0000269|PubMed:18719106, ECO:0000269|PubMed:18794347,
CC       ECO:0000269|PubMed:19419956, ECO:0000269|PubMed:19443450,
CC       ECO:0000269|PubMed:20457750, ECO:0000269|PubMed:21549307,
CC       ECO:0000269|PubMed:21628590, ECO:0000269|PubMed:22153967,
CC       ECO:0000269|PubMed:22634751, ECO:0000269|PubMed:22681887,
CC       ECO:0000269|PubMed:22704558, ECO:0000269|PubMed:22705370,
CC       ECO:0000269|PubMed:22759634, ECO:0000269|PubMed:23000965,
CC       ECO:0000269|PubMed:23711367, ECO:0000269|PubMed:24115439,
CC       ECO:0000269|PubMed:24561620, ECO:0000269|PubMed:24911150,
CC       ECO:0000269|PubMed:24939902, ECO:0000269|PubMed:9302295,
CC       ECO:0000269|PubMed:9305916, ECO:0000269|PubMed:9566895}.
CC   -!- INTERACTION:
CC       Self; NbExp=5; IntAct=EBI-358311, EBI-358311;
CC       Q8TE30:-; NbExp=6; IntAct=EBI-358311, EBI-8874509;
CC       P04075:ALDOA; NbExp=3; IntAct=EBI-358311, EBI-709613;
CC       P38936:CDKN1A; NbExp=15; IntAct=EBI-358311, EBI-375077;
CC       P42771:CDKN2A; NbExp=8; IntAct=EBI-358311, EBI-375053;
CC       Q9H211:CDT1; NbExp=2; IntAct=EBI-358311, EBI-456953;
CC       Q13111:CHAF1A; NbExp=3; IntAct=EBI-358311, EBI-1020839;
CC       P06733:ENO1; NbExp=3; IntAct=EBI-358311, EBI-353877;
CC       P39748:FEN1; NbExp=4; IntAct=EBI-358311, EBI-707816;
CC       Q9Z111:Gadd45g (xeno); NbExp=9; IntAct=EBI-358311, EBI-1173616;
CC       P04406:GAPDH; NbExp=3; IntAct=EBI-358311, EBI-354056;
CC       Q9H160:ING2; NbExp=3; IntAct=EBI-358311, EBI-389787;
CC       P20585:MSH3; NbExp=3; IntAct=EBI-358311, EBI-1164205;
CC       P18669:PGAM1; NbExp=2; IntAct=EBI-358311, EBI-717905;
CC       P28340:POLD1; NbExp=2; IntAct=EBI-358311, EBI-716569;
CC       Q15054:POLD3; NbExp=4; IntAct=EBI-358311, EBI-864956;
CC       Q9HCU8:POLD4; NbExp=4; IntAct=EBI-358311, EBI-864968;
CC       A2RU14:TMEM218; NbExp=3; IntAct=EBI-358311, EBI-10173151;
CC       P60174:TPI1; NbExp=2; IntAct=EBI-358311, EBI-717475;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24115439,
CC       ECO:0000269|PubMed:24939902}. Note=Colocalizes with CREBBP, EP300
CC       and POLD1 to sites of DNA damage (PubMed:24939902). Forms nuclear
CC       foci representing sites of ongoing DNA replication and vary in
CC       morphology and number during S phase. Together with APEX2, is
CC       redistributed in discrete nuclear foci in presence of oxidative
CC       DNA damaging agents. {ECO:0000269|PubMed:24939902}.
CC   -!- PTM: Phosphorylated. Phosphorylation at Tyr-211 by EGFR stabilizes
CC       chromatin-associated PCNA. {ECO:0000269|PubMed:17115032}.
CC   -!- PTM: Acetylated by CREBBP and p300/EP300; preferentially
CC       acetylated by CREBBP on Lys-80, Lys-13 and Lys-14 and on Lys-77 by
CC       p300/EP300 upon loading on chromatin in response to UV irradiation
CC       (PubMed:24939902, PubMed:19419956). Lysine acetylation disrupts
CC       association with chromatin, hence promoting PCNA ubiquitination
CC       and proteasomal degradation in response to UV damage in a CREBBP-
CC       and EP300-dependent manner (PubMed:24939902). Acetylation disrupts
CC       interaction with NUDT15 and promotes degradation
CC       (PubMed:19419956). {ECO:0000269|PubMed:24939902}.
CC   -!- PTM: Ubiquitinated (PubMed:24939902). Following DNA damage, can be
CC       either monoubiquitinated to stimulate direct bypass of DNA lesions
CC       by specialized DNA polymerases or polyubiquitinated to promote
CC       recombination-dependent DNA synthesis across DNA lesions by
CC       template switching mechanisms. Following induction of replication
CC       stress, monoubiquitinated by the UBE2B-RAD18 complex on Lys-164,
CC       leading to recruit translesion (TLS) polymerases, which are able
CC       to synthesize across DNA lesions in a potentially error-prone
CC       manner. An error-free pathway also exists and requires non-
CC       canonical polyubiquitination on Lys-164 through 'Lys-63' linkage
CC       of ubiquitin moieties by the E2 complex UBE2N-UBE2V2 and the E3
CC       ligases, HLTF, RNF8 and SHPRH. This error-free pathway, also known
CC       as template switching, employs recombination mechanisms to
CC       synthesize across the lesion, using as a template the undamaged,
CC       newly synthesized strand of the sister chromatid.
CC       Monoubiquitination at Lys-164 also takes place in undamaged
CC       proliferating cells, and is mediated by the DCX(DTL) complex,
CC       leading to enhance PCNA-dependent translesion DNA synthesis.
CC       Sumoylated during S phase. {ECO:0000269|PubMed:15149598,
CC       ECO:0000269|PubMed:17108083, ECO:0000269|PubMed:17130289,
CC       ECO:0000269|PubMed:18316726, ECO:0000269|PubMed:18719106,
CC       ECO:0000269|PubMed:18948756, ECO:0000269|PubMed:20129063,
CC       ECO:0000269|PubMed:22153967, ECO:0000269|PubMed:24939902}.
CC   -!- PTM: Methylated on glutamate residues by ARMT1/C6orf211.
CC       {ECO:0000269|PubMed:25732820}.
CC   -!- DISEASE: Ataxia-telangiectasia-like disorder 2 (ATLD2)
CC       [MIM:615919]: A neurodegenerative disorder due to defects in DNA
CC       excision repair. ATLD2 is characterized by developmental delay,
CC       ataxia, sensorineural hearing loss, short stature, cutaneous and
CC       ocular telangiectasia, and photosensitivity.
CC       {ECO:0000269|PubMed:24911150}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Antibodies against PCNA are present in sera from
CC       patients with systemic lupus erythematosus.
CC   -!- SIMILARITY: Belongs to the PCNA family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pcna/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=PCNA entry;
CC       URL="http://en.wikipedia.org/wiki/PCNA";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PCNAID41670ch20p12.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M15796; AAA35736.1; -; mRNA.
DR   EMBL; J04718; AAA60040.1; -; Genomic_DNA.
DR   EMBL; AF527838; AAM78556.1; -; Genomic_DNA.
DR   EMBL; AK313286; BAG36094.1; -; mRNA.
DR   EMBL; AL121924; CAC27344.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10428.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10429.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10430.1; -; Genomic_DNA.
DR   EMBL; BC000491; AAH00491.1; -; mRNA.
DR   EMBL; BC062439; AAH62439.1; -; mRNA.
DR   CCDS; CCDS13087.1; -.
DR   PIR; A27445; WMHUET.
DR   RefSeq; NP_002583.1; NM_002592.2.
DR   RefSeq; NP_872590.1; NM_182649.1.
DR   UniGene; Hs.147433; -.
DR   UniGene; Hs.744934; -.
DR   PDB; 1AXC; X-ray; 2.60 A; A/C/E=1-261.
DR   PDB; 1U76; X-ray; 2.60 A; A/C/E=1-261.
DR   PDB; 1U7B; X-ray; 1.88 A; A=1-261.
DR   PDB; 1UL1; X-ray; 2.90 A; A/B/C=1-261.
DR   PDB; 1VYJ; X-ray; 2.80 A; A/C/E/G/I/K=1-261.
DR   PDB; 1VYM; X-ray; 2.30 A; A/B/C=1-261.
DR   PDB; 1W60; X-ray; 3.15 A; A/B=1-261.
DR   PDB; 2ZVK; X-ray; 2.70 A; A/B/C=1-261.
DR   PDB; 2ZVL; X-ray; 2.50 A; A/B/C/D/E/F=1-261.
DR   PDB; 2ZVM; X-ray; 2.30 A; A/B/C=1-261.
DR   PDB; 3P87; X-ray; 2.99 A; A/B/C/D/E/F=1-261.
DR   PDB; 3TBL; X-ray; 2.90 A; A/B/C=1-261.
DR   PDB; 3VKX; X-ray; 2.10 A; A=1-261.
DR   PDB; 3WGW; X-ray; 2.80 A; A/B=1-261.
DR   PDB; 4D2G; X-ray; 2.65 A; A/B/C=1-261.
DR   PDBsum; 1AXC; -.
DR   PDBsum; 1U76; -.
DR   PDBsum; 1U7B; -.
DR   PDBsum; 1UL1; -.
DR   PDBsum; 1VYJ; -.
DR   PDBsum; 1VYM; -.
DR   PDBsum; 1W60; -.
DR   PDBsum; 2ZVK; -.
DR   PDBsum; 2ZVL; -.
DR   PDBsum; 2ZVM; -.
DR   PDBsum; 3P87; -.
DR   PDBsum; 3TBL; -.
DR   PDBsum; 3VKX; -.
DR   PDBsum; 3WGW; -.
DR   PDBsum; 4D2G; -.
DR   ProteinModelPortal; P12004; -.
DR   SMR; P12004; 1-255.
DR   BioGrid; 111142; 231.
DR   DIP; DIP-1098N; -.
DR   IntAct; P12004; 54.
DR   MINT; MINT-5000943; -.
DR   STRING; 9606.ENSP00000368438; -.
DR   BindingDB; P12004; -.
DR   ChEMBL; CHEMBL2346488; -.
DR   PhosphoSite; P12004; -.
DR   BioMuta; PCNA; -.
DR   DMDM; 129694; -.
DR   SWISS-2DPAGE; P12004; -.
DR   MaxQB; P12004; -.
DR   PaxDb; P12004; -.
DR   PeptideAtlas; P12004; -.
DR   PRIDE; P12004; -.
DR   DNASU; 5111; -.
DR   Ensembl; ENST00000379143; ENSP00000368438; ENSG00000132646.
DR   Ensembl; ENST00000379160; ENSP00000368458; ENSG00000132646.
DR   GeneID; 5111; -.
DR   KEGG; hsa:5111; -.
DR   UCSC; uc002wlp.3; human.
DR   CTD; 5111; -.
DR   GeneCards; GC20M005095; -.
DR   HGNC; HGNC:8729; PCNA.
DR   HPA; CAB000148; -.
DR   HPA; HPA030521; -.
DR   HPA; HPA030522; -.
DR   HPA; HPA030523; -.
DR   MIM; 176740; gene.
DR   MIM; 615919; phenotype.
DR   neXtProt; NX_P12004; -.
DR   PharmGKB; PA263; -.
DR   eggNOG; COG0592; -.
DR   GeneTree; ENSGT00390000004965; -.
DR   HOGENOM; HOG000211098; -.
DR   HOVERGEN; HBG000947; -.
DR   InParanoid; P12004; -.
DR   KO; K04802; -.
DR   OMA; KMMDIDS; -.
DR   OrthoDB; EOG7JX34W; -.
DR   PhylomeDB; P12004; -.
DR   TreeFam; TF313441; -.
DR   Reactome; REACT_111214; G0 and Early G1.
DR   Reactome; REACT_1287; Translesion Synthesis by POLH.
DR   Reactome; REACT_1385; Processive synthesis on the lagging strand.
DR   Reactome; REACT_1792; Polymerase switching.
DR   Reactome; REACT_1838; Leading Strand Synthesis.
DR   Reactome; REACT_1993; Repair synthesis for gap-filling by DNA polymerase in TC-NER.
DR   Reactome; REACT_264347; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta).
DR   Reactome; REACT_264501; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha).
DR   Reactome; REACT_355158; Translesion synthesis by POLK.
DR   Reactome; REACT_355250; Termination of translesion DNA synthesis.
DR   Reactome; REACT_355324; Translesion synthesis by POLI.
DR   Reactome; REACT_355480; Recognition of DNA damage by PCNA-containing replication complex.
DR   Reactome; REACT_355510; PCNA-Dependent Long Patch Base Excision Repair.
DR   Reactome; REACT_378; Repair synthesis of patch ~27-30 bases long by DNA polymerase.
DR   Reactome; REACT_471; E2F mediated regulation of DNA replication.
DR   Reactome; REACT_683; G1/S-Specific Transcription.
DR   Reactome; REACT_70; Removal of the Flap Intermediate.
DR   Reactome; REACT_7961; Telomere C-strand (Lagging Strand) Synthesis.
DR   Reactome; REACT_7987; Polymerase switching on the C-strand of the telomere.
DR   Reactome; REACT_7999; Removal of the Flap Intermediate from the C-strand.
DR   Reactome; REACT_8; Translesion synthesis by REV1.
DR   Reactome; REACT_8027; Processive synthesis on the C-strand of the telomere.
DR   SignaLink; P12004; -.
DR   ChiTaRS; PCNA; human.
DR   EvolutionaryTrace; P12004; -.
DR   GeneWiki; Proliferating_cell_nuclear_antigen; -.
DR   GenomeRNAi; 5111; -.
DR   NextBio; 19722; -.
DR   PRO; PR:P12004; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; P12004; -.
DR   CleanEx; HS_PCNA; -.
DR   Genevisible; P12004; HS.
DR   GO; GO:0005813; C:centrosome; IDA:MGI.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005663; C:DNA replication factor C complex; TAS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043596; C:nuclear replication fork; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043626; C:PCNA complex; IDA:UniProtKB.
DR   GO; GO:0070557; C:PCNA-p21 complex; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0032139; F:dinucleotide insertion or deletion binding; IDA:BHF-UCL.
DR   GO; GO:0070182; F:DNA polymerase binding; IPI:UniProtKB.
DR   GO; GO:0030337; F:DNA polymerase processivity factor activity; IBA:GO_Central.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0032405; F:MutLalpha complex binding; IDA:HGNC.
DR   GO; GO:0000701; F:purine-specific mismatch base pair DNA N-glycosylase activity; IDA:BHF-UCL.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:UniProtKB.
DR   GO; GO:0006284; P:base-excision repair; TAS:Reactome.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0042769; P:DNA damage response, detection of DNA damage; TAS:Reactome.
DR   GO; GO:0006281; P:DNA repair; TAS:Reactome.
DR   GO; GO:0006271; P:DNA strand elongation involved in DNA replication; TAS:Reactome.
DR   GO; GO:0030855; P:epithelial cell differentiation; IEP:UniProtKB.
DR   GO; GO:0070987; P:error-free translesion synthesis; TAS:Reactome.
DR   GO; GO:0042276; P:error-prone translesion synthesis; TAS:Reactome.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0006272; P:leading strand elongation; IBA:GO_Central.
DR   GO; GO:0006298; P:mismatch repair; IDA:BHF-UCL.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0006289; P:nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0006297; P:nucleotide-excision repair, DNA gap filling; TAS:Reactome.
DR   GO; GO:0032077; P:positive regulation of deoxyribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0045739; P:positive regulation of DNA repair; IMP:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IMP:UniProtKB.
DR   GO; GO:0000083; P:regulation of transcription involved in G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0033993; P:response to lipid; IEA:Ensembl.
DR   GO; GO:0000723; P:telomere maintenance; TAS:Reactome.
DR   GO; GO:0000722; P:telomere maintenance via recombination; TAS:Reactome.
DR   GO; GO:0032201; P:telomere maintenance via semi-conservative replication; TAS:Reactome.
DR   GO; GO:0006283; P:transcription-coupled nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0019985; P:translesion synthesis; IDA:UniProtKB.
DR   HAMAP; MF_00317; DNApol_clamp_arch; 1.
DR   InterPro; IPR000730; Pr_cel_nuc_antig.
DR   InterPro; IPR022649; Pr_cel_nuc_antig_C.
DR   InterPro; IPR022659; Pr_cel_nuc_antig_CS.
DR   InterPro; IPR022648; Pr_cel_nuc_antig_N.
DR   PANTHER; PTHR11352; PTHR11352; 1.
DR   Pfam; PF02747; PCNA_C; 1.
DR   Pfam; PF00705; PCNA_N; 1.
DR   PRINTS; PR00339; PCNACYCLIN.
DR   TIGRFAMs; TIGR00590; pcna; 1.
DR   PROSITE; PS01251; PCNA_1; 1.
DR   PROSITE; PS00293; PCNA_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Deafness;
KW   Direct protein sequencing; Disease mutation; DNA damage; DNA repair;
KW   DNA replication; DNA-binding; Dwarfism; Isopeptide bond; Methylation;
KW   Neurodegeneration; Nucleus; Phosphoprotein; Reference proteome;
KW   Ubl conjugation.
FT   CHAIN         1    261       Proliferating cell nuclear antigen.
FT                                /FTId=PRO_0000149158.
FT   DNA_BIND     61     80       {ECO:0000255}.
FT   REGION        7    100       Interaction with NUDT15.
FT   MOD_RES      14     14       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19419956}.
FT   MOD_RES      77     77       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES      80     80       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES     211    211       Phosphotyrosine; by EGFR.
FT                                {ECO:0000269|PubMed:17115032}.
FT   MOD_RES     248    248       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   CROSSLNK    164    164       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:17108083,
FT                                ECO:0000269|PubMed:17130289}.
FT   VARIANT     228    228       S -> I (in ATLD2; a hypomorphic mutation
FT                                affecting DNA repair in response to UV;
FT                                results in significantly decreased
FT                                interaction with FEN1, LIG1 and ERCC5).
FT                                {ECO:0000269|PubMed:24911150}.
FT                                /FTId=VAR_071871.
FT   MUTAGEN      13     13       K->R: Inhibits acetylation, recruitement
FT                                to DNA damage sites, inducible
FT                                ubiquitination and protein degradation,
FT                                DNA replication and repair synthesis
FT                                efficiencies, but homotrimer formation,
FT                                nuclear recruitement to DNA damage sites,
FT                                interactions with CREBBP, EP300 and POLD1
FT                                are similar as the wild-type; in
FT                                association with R-14; R-20; R-77 and R-
FT                                80. {ECO:0000269|PubMed:24939902}.
FT   MUTAGEN      14     14       K->R: Inhibits acetylation, recruitement
FT                                to DNA damage sites, inducible
FT                                ubiquitination and protein degradation,
FT                                DNA replication and repair synthesis
FT                                efficiencies, but homotrimer formation,
FT                                nuclear recruitement to DNA damage sites,
FT                                interactions with CREBBP, EP300 and POLD1
FT                                are similar as the wild-type; in
FT                                association with R-13; R-20; R-77 and R-
FT                                80. {ECO:0000269|PubMed:24939902}.
FT   MUTAGEN      20     20       K->R: Inhibits acetylation, recruitement
FT                                to DNA damage sites, inducible
FT                                ubiquitination and protein degradation,
FT                                DNA replication and repair synthesis
FT                                efficiencies, but homotrimer formation,
FT                                nuclear recruitement to DNA damage sites,
FT                                interactions with CREBBP, EP300 and POLD1
FT                                are similar as the wild-type; in
FT                                association with R-13; R-14; R-77 and R-
FT                                80. {ECO:0000269|PubMed:24939902}.
FT   MUTAGEN      77     77       K->A: Inhibits recruitement to DNA damage
FT                                sites, but nuclear localization is
FT                                similar as the wild-type; in association
FT                                with A-80. {ECO:0000269|PubMed:24939902}.
FT   MUTAGEN      77     77       K->R: Inhibits acetylation, recruitement
FT                                to DNA damage sites, inducible
FT                                ubiquitination and protein degradation,
FT                                DNA replication and repair synthesis
FT                                efficiencies, but homotrimer formation,
FT                                nuclear recruitement to DNA damage sites,
FT                                interactions with CREBBP, EP300 and POLD1
FT                                are similar as the wild-type; in
FT                                association with R-13; R-14; R-20 and R-
FT                                80. {ECO:0000269|PubMed:24939902}.
FT   MUTAGEN      80     80       K->A: Inhibits recruitement to DNA damage
FT                                sites, but nuclear localization is
FT                                similar as the wild-type; in association
FT                                with A-77. {ECO:0000269|PubMed:24939902}.
FT   MUTAGEN      80     80       K->R: Inhibits acetylation, recruitement
FT                                to DNA damage sites, inducible
FT                                ubiquitination and protein degradation,
FT                                DNA replication and repair synthesis
FT                                efficiencies, but homotrimer formation,
FT                                nuclear recruitement to DNA damage sites,
FT                                interactions with CREBBP, EP300 and POLD1
FT                                are similar as the wild-type; in
FT                                association with R-13; R-14; R-20 and R-
FT                                77. {ECO:0000269|PubMed:24939902}.
FT   MUTAGEN     164    164       K->R: Abolishes ubiquitination. No effect
FT                                on interaction with SHPRH.
FT                                {ECO:0000269|PubMed:17108083,
FT                                ECO:0000269|PubMed:17130289,
FT                                ECO:0000269|PubMed:18719106,
FT                                ECO:0000269|PubMed:20129063}.
FT   MUTAGEN     211    211       Y->F: Alters chromatin-associated PCNA
FT                                stability and its function in DNA
FT                                replication and repair.
FT                                {ECO:0000269|PubMed:17115032}.
FT   STRAND        2      7       {ECO:0000244|PDB:1U7B}.
FT   HELIX        10     20       {ECO:0000244|PDB:1U7B}.
FT   STRAND       24     31       {ECO:0000244|PDB:1U7B}.
FT   STRAND       34     40       {ECO:0000244|PDB:1U7B}.
FT   STRAND       44     53       {ECO:0000244|PDB:1U7B}.
FT   HELIX        54     56       {ECO:0000244|PDB:1U7B}.
FT   STRAND       57     64       {ECO:0000244|PDB:1U7B}.
FT   STRAND       66     71       {ECO:0000244|PDB:1U7B}.
FT   HELIX        72     79       {ECO:0000244|PDB:1U7B}.
FT   STRAND       87     92       {ECO:0000244|PDB:1U7B}.
FT   STRAND       94     96       {ECO:0000244|PDB:1VYM}.
FT   STRAND       97    104       {ECO:0000244|PDB:1U7B}.
FT   STRAND      106    108       {ECO:0000244|PDB:2ZVL}.
FT   STRAND      111    117       {ECO:0000244|PDB:1U7B}.
FT   STRAND      121    127       {ECO:0000244|PDB:1AXC}.
FT   STRAND      134    140       {ECO:0000244|PDB:1U7B}.
FT   HELIX       141    152       {ECO:0000244|PDB:1U7B}.
FT   STRAND      156    163       {ECO:0000244|PDB:1U7B}.
FT   STRAND      166    173       {ECO:0000244|PDB:1U7B}.
FT   STRAND      176    182       {ECO:0000244|PDB:1U7B}.
FT   TURN        191    193       {ECO:0000244|PDB:4D2G}.
FT   STRAND      196    201       {ECO:0000244|PDB:1U7B}.
FT   STRAND      203    208       {ECO:0000244|PDB:1U7B}.
FT   HELIX       209    215       {ECO:0000244|PDB:1U7B}.
FT   HELIX       216    221       {ECO:0000244|PDB:1U7B}.
FT   STRAND      223    229       {ECO:0000244|PDB:1U7B}.
FT   STRAND      231    233       {ECO:0000244|PDB:1VYM}.
FT   STRAND      235    241       {ECO:0000244|PDB:1U7B}.
FT   TURN        242    244       {ECO:0000244|PDB:1U7B}.
FT   STRAND      245    251       {ECO:0000244|PDB:1U7B}.
SQ   SEQUENCE   261 AA;  28769 MW;  E6F08E7EDBC48B00 CRC64;
     MFEARLVQGS ILKKVLEALK DLINEACWDI SSSGVNLQSM DSSHVSLVQL TLRSEGFDTY
     RCDRNLAMGV NLTSMSKILK CAGNEDIITL RAEDNADTLA LVFEAPNQEK VSDYEMKLMD
     LDVEQLGIPE QEYSCVVKMP SGEFARICRD LSHIGDAVVI SCAKDGVKFS ASGELGNGNI
     KLSQTSNVDK EEEAVTIEMN EPVQLTFALR YLNFFTKATP LSSTVTLSMS ADVPLVVEYK
     IADMGHLKYY LAPKIEDEEG S
//
